PT  - JOURNAL ARTICLE
AU  - Eric M. Rohren
AU  - Elba C. Etchebehere
AU  - John C. Araujo
AU  - Brian P. Hobbs
AU  - Nancy M. Swanston
AU  - Michael Everding
AU  - Tracy Moody
AU  - Homer A. Macapinlac
TI  - Determination of Skeletal Tumor Burden on <sup>18</sup>F-Fluoride PET/CT
AID  - 10.2967/jnumed.115.156026
DP  - 2015 Oct 01
TA  - Journal of Nuclear Medicine
PG  - 1507--1512
VI  - 56
IP  - 10
4099  - http://jnm.snmjournals.org/content/56/10/1507.short
4100  - http://jnm.snmjournals.org/content/56/10/1507.full
SO  - J Nucl Med2015 Oct 01; 56
AB  - The purpose of this study was to define a method to assess skeletal tumor burden with 18F-labeled sodium fluoride PET/CT (18F-fluoride PET/CT) and evaluate the reproducibility of these measurements. Methods: Ninety-eight consecutive patients (90 men; mean age ± SD, 65.7 ± 14.2 y) underwent 158 18F-fluoride PET/CT scans for evaluation of skeletal metastatic disease. In order to determine the mean normal bone SUV, initially a 1-cm spheric volume of interest (VOI) was placed over 5 bone sites: T12, L5, sacrum, right iliac bone, and right femur. For each patient, the mean SUVmax for all sites was generated. Afterward, a threshold value of normal bone uptake was established. Subsequently, skeletal tumor burden was determined by generating volumetric data using a whole-body segmentation method. Any SUVmax below the normal threshold was excluded from analysis, as were VOIs not related to metastatic disease. Statistics for the remaining VOIs were then generated and defined as the skeletal metastatic tumor burden by 2 parameters: total lesion fluoride uptake above an SUVmax of 10 (TLF10) and fluoride tumor volume above an SUVmax of 10 (FTV10). TLF10 and FTV10 reproducibility was determined using 2 independent and experienced PET/CT interpreters analyzing a subset of 13 18F-fluoride PET/CT scans. Results: Mean (±SD) normal bone SUVmax was 6.62 ± 1.55 for T12, 6.11 ± 1.73 for L5, 4.59 ± 1.74 for sacrum, 5.39 ± 1.72 for right iliac bone, and 3.90 ± 1.57 for right femur. The mean normal SUVmax for all 543 sites was 5.32 ± 0.99. On the basis of these values, an SUVmax threshold of 10 was chosen to exclude normal bone from the volumetric calculations. Semiautomated measurements of TLF10 and FTV10 exhibited high interobserver reproducibility, within ±0.77% and ±3.62% of the interinterpreter average for TLF10 and FTV10, respectively. Conclusion: Determination of skeletal tumor burden with 18F-fluoride PET/CT is feasible and highly reproducible. Using an SUVmax threshold of 10 excludes nearly all normal bone activity from volumetric calculations.